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Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are the 
most  widely  used  therapeutic  agents.
1  According  to 
Mintzes (2012), more than 100 million prescriptions of 
NSAIDs were made throughout the world, which media 
was the main route for advertising.
2 Mefenamic acid is 
used for inflammatory pain such as dental pain or after 
traumas.  Despite  the  wide  usage,  they  cause  a  large 
variety  of  serious  toxicity  which  include  severe 
gastrointestinal  tract  disorders,  hepatotoxicity  and 
nephrotoxicity.
3  
Like other NSAIDs, mefenamic acid or Ponstan (2',3'-
dimethyl-N-phenyl-anthranilic  acid)  (Figure  1),  inhibits 
prostaglandin  biosynthesis.  This  effect  may  be 
responsible  for  the  analgesic,  antipyretic  and  anti-
inflammatory  properties  of  all  drugs  of  this  group.
4  In 
spite of the potential for nephrotoxicity, particularly in 
the elderly, the drug continues to be widely used at high 
dosage in patients.
5 NSAIDs have produced a variety of 
distinct  renal  syndromes  which  include  acute  ischemic 
renal insufficiency and acute interstitial nephritis caused 
by haemodynamic effect, which is a direct result of COX 
inhibition.
6,7  Analgesic-associated  nephropathy  is  a 
severe  adverse  reaction,  where  the  cause  remains 
unknown.
8,9 We have reported previously that mefenamic 
acid  induced  hepatotoxicity  in  an  animal  model.
10 
However, in this current investigation, we evaluated the 
nephrotoxicity  caused  by  mefenamic  acid  in  mice  and 
determine  the  usefulness  of  this  animal  model  in 
studying the mechanism of nephrotoxicity. 
 
 
Figure 1. Chemical Structure of mefenamic acid 
 
Materials and Methods 
Mefenamic acid (Ponstan) was purchased from United 
Pharma Ltd. Baar, Switzerland. All other chemicals were 
of analytical grade were purchased from Sigma Chemicals 
or BDH, UK. Male Balb/c mice from Institute of Medical 
Research  (IMR),  Malaysia  30-40g  in  bodyweight  were 
kept in plastic cages (8 mice/cage) with wood shavings as 
bedding. They were made to acclimatize to the vivarium 
environment  for  1  week.  They  were  fed  standard 
laboratory  pellets  with  tap  water  ad  libitum.  All 
procedures are approved by the Institutional Animal Care 
and Use Committee (ACUC). 
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Abstract 
Purpose:  Nonsteroidal  anti-inflammatory  drugs  (NSAIDs)  are  used  for  the  treatment  of 
many joint disorders, inflammation and to control pain. Numerous reports have indicated 
that NSAIDs are capable of producing nephrotoxicity in human. Therefore, the objective of 
this study was to evaluate mefenamic acid, a NSAID nephrotoxicity in an animal model. 
Methods: Mice were dosed intraperitoneally with mefenamic acid either as a single dose 
(100 or 200 mg/kg in 10% Dimethyl sulfoxide/Palm oil) or as single daily doses for 14 days 
(50 or 100 mg/kg in 10% Dimethyl sulfoxide/Palm oil per day). Venous blood samples from 
mice during the dosing period were taken prior to and 14 days post-dosing from cardiac 
puncture into heparinized vials. Plasma blood urea nitrogen (BUN) and creatinine activities 
were measured. 
Results: Single dose of mefenamic acid induced mild alteration of kidney histology mainly 
mild glomerular necrosis and tubular atrophy. Interestingly, chronic doses induced a dose 
dependent glomerular necrosis, massive degeneration, inflammation and tubular atrophy. 
Plasma blood urea nitrogen was statistically elevated in mice treated with mefenamic acid 
for 14 days similar to plasma creatinine. 
Conclusion: Results from this study suggest that mefenamic acid as with other NSAIDs 
capable  of  producing  nephrotoxicity.  Therefore,  the  study  of  the  exact  mechanism  of 
mefenamic acid induced severe nephrotoxicity can be done in this animal model. 
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The  mice  (n=8/group)  received  single  intraperitoneal 
injections of mefenamic acid (at 100 or 200 mg/kg in 10% 
Dimethyl  sulfoxide/Palm  oil)  or  daily  intraperitoneal 
dosing  (at  50  or  100  mg/kg  in  10%  Dimethyl 
sulfoxide/Palm oil) for 14 days. Control animals received 
equivalent amount of vehicle.  
Venous blood samples from mice during the dosing period 
(100 µl) were taken prior to and 14 days post-dosing from 
cardiac  puncture  into  heparinized  vials  (0.3  mL  vials 
containing  15  UmL-1  lithium  heparin:  Sarstedt,  UK). 
Blood samples were centrifuged at 4000 rpm for 15 min 
and  the  plasma  transferred  to  0.5  mL  plastic  eppendorf 
tubes, stored at  -20°C  until analysis.  Plasma blood  urea 
nitrogen (BUN) activity was measured using a commercial 
kit (Sigma Chemicals, UK). BUN levels were calculated 
from the decrease in NADH absorbance at λ 340 nm using 
a  BUN  Sigma  standard.  Plasma  creatinine  level  was 
performed with an automatic chemical analyzer  (Hitachi 
Roche 902, Japan).  Six hours after  the final dose,  mice 
were sacrificed by cervical dislocation and their kidneys 
removed. A section was fixed in formalin for 24 hr before 
processing for histological examination. 
Data are expressed as mean + s.d and were analyzed for 
statistical significance (p<0.05) using analysis of variance 
(ANOVA) with Duncan multiple post test or Student’s t 
test. 
 
Results 
Figure  2  demonstrates  mefenamic  acid-induced 
nephrotoxicity.  BUN  levels  were  determined  in  this 
study, since changes in serum BUN level are considered 
as the marker for kidney functions. BUN is regulated by 
the metabolism of proteins and the rate of renal excretion 
of urea nitrogen. All doses of mefenamic acid were able 
to induce nephrotoxicity as measured by sharp increases 
in BUN that exceeded control (20 mg/dl) by greater than 
3-fold  (50  mg/kg/day:  62  mg/dl)  and  6.5-fold  (100 
mg/kg: 130 mg/dl). Similar trends were also observed for 
creatinine  parameter  (Table  1).  The  single  doses  of 
mefenamic  acid  revealed  normal  plasma  BUN  and 
creatinine activities.  
 
 
Figure 2. Blood Urea Nitrogen activity in mice treated with 
mefenamic acid 
Mean  with  different  superscript  differ  significantly  (p<0.05). 
n=8/group 
Table 1. Plasma creatinine level of mice 
 Group (n=8) mg/kg mefenamic acid  Pre treatment  Post Treatment 
Single doses 
0  0.37 + 0.003
ax  0.47 + 0.016
ax 
100  0.43 + 0.012
ax  0.33 + 0.042
ax 
200  0.39 + 0.025
ax  0.31 + 0.075
ax 
14 days doses 
0  0.27 + 0.034
ax  0.47 + 0.022
ax 
50  0.53 + 0.078
ax  0.79 + 0.011
by 
100  0.34 + 0.065
ax  0.99 + 0.075
by 
a-cMean  with  different  superscript  differ  significantly  in  the 
same column(p<0.05). n=8/group 
x-y  Mean  with  different  superscript  differ  significantly  in  the 
same row(p<0.05). n=8/group 
 
Histopathological examination of kidney sections vividly 
mirrored  the  biochemical  findings.  Some  necrotic 
glomeruli were observed at renal cortex of mice treated 
with single doses of 100mg/kg mefenamic acid. At renal 
medulla,  there  was  presence  of  tubular  atrophy. 
200mg/kg of mefenamic acid in single doses produced 
glomerular  necrosis  and  medullary  tubular  atrophy 
(Figure 3A). There were also some cortical and papillary 
tubular  congestion  with  eosinophilic  secretory  material 
in the tubular lumen. 
Repeated doses (50mg/kg and 100mg/kg) of mefenamic 
acid produces the same lesions with glomerular necrosis 
and  medullary  tubular  atrophy.  However,  the  lesions 
were more severe. The focal infiltration of inflammatory 
cells seen at renal cortex of mice treated repeatedly with 
100mg/kg  mefenamic  acid  (Figure  3B  and  3C)  is  also 
seen  in  the  rare  interstitial  nephritis  associated  with 
chronic use of NSAIDs.
9 Papillary necrosis, which was 
suggested  as  the  potential  mechanism  of  nephropathy 
induced  by  mefenamic  acid  was  not  detected  in  this 
study.
1 However, papillary tubular atrophy was observed 
in all (single and repeated doses) mefenamic acid treated 
mice (Figure 3D). The controls showed normal histology 
at  both  renal  cortex  and  medulla  (Figure  3E  and  3F). 
Proximal  convoluted  tubules  with  smaller  amount  of 
distal  convoluted  tubules  making  up  the  bulk  of  the 
parenchyma. 
 
Discussion  
An  astounding  number  of  prescriptions  (over  100 
million)  are  written  every  year  for  NSAIDs.
2  This 
number  is  excluding  those  which  are  available  as 
nonprescription agents. The 2009 Annual Report of the 
American  Association  of  Poison  Control  Centers’ 
National  Poison  Data  System  (NPDS)  showed  that 
NSAIDs  were  the  most  common  in  acute  overdose  in 
adult  patients.
11  They  are  popular  analgesics  of  choice 
due to the potency, often used clinically for the short-
term  alleviation  of  postoperative  pain,  dysmenrrhoea, 
and  gastrointestinal  complications.
1  However,  severe 
renal  dysfunctions  are  occasional  consequences  of  its 
toxicity.
5,6 Although mefenamic acid is extensively used, 
mechanisms  for  causing  multiorgan  toxicity  remain 
unknown.  
Mefenamic acid induced kidney damage but results from 
this current investigation revealed that the kidney lesions  
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were  mild  and  not  life  threatening  for  single  doses  of 
mefenamic acid. However, repeated doses of mefenamic 
acid caused severe lesions in the kidney. Further studies 
are  needed  to  elucidate  the  mechanism  of  which 
mefenamic  acid  induced  severe  nephopathy. 
Approximately 1–5% of patients taking NSAIDs develop 
diverse  nephrotoxic  syndromes  warranting  potential 
physician  intervention.
12  Fortunately,  NSAID-induced 
renal  complications  are  typically  fully  reversible  if  the 
clinician suspects NSAID complications when presented 
with  laboratory  and  histologic  findings,  and  swiftly 
discontinues the offending NSAID.
13 
 
 
Figure 3. Histopathological changes in the kidneys of mice treated with mefenamic acid. 
A:  Mild interstitial nephritis in the renal cortex of mouse (Arrow) received 200 mg/kg mefenamic acid for 1 day (Mag. 400x) 
B: Interstitial nephritis and glomerular necrosis (Arrows) in the renal cortex of mouse received 100 mg/kg mefanamic acid for 14 days 
(Mag. 400x) 
C: Interstitial nephritis in the renal cortex of mouse (Arrow) received 100 mg/kg mefanamic acid for 14 days (Mag. 400x) 
D: Medullary tubular atrophy (Arrows) of mouse received 100 mg/kg mefanamic acid for 14 days (Mag. 400x) 
E: Section from control mouse showing normal renal cortex histology (Mag. 400x) 
F: Section from control mouse showing normal renal medulla histology (Mag. 400x) 
 
The  mechanism  suggested  is  the  involvement  of 
prostaglandin I2 and PGE2 which are synthesized by both 
the  glomerular  and  medullary  interstitial  cells. 
Prostaglandins  will  diminish  vascular  resistance,  dilate 
renal vascular  beds and  enhance organ  perfusion.  This 
will lead to redistribution of blood flow from the renal 
cortex  to  nephrons  in  the  juxtamedullary  region.
14 
NSAIDs inhibit  prostaglandin  synthesis,  decreasing  the 
blood  supply  to  the  nephrons  causing  acute  ischemic 
renal insufficiency.  
Due  to  numerous  reports  for  adverse  drug  reactions 
(ADRs) induced by NSAIDs, researchers have come up 
with  new  strategies  for  lowering  ADRs  by  improving 
their  efficacy  through  drug  delivery.
15,16  Work  on  
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piroxicam,  another  NSAID  has  revealed  exciting 
findings  of  significantly  improve  its  efficacy  by  nano-
encapsulation  with  much  reduced  ADRs.
17  Synthetic 
drugs  are  usually  induce  more  ADRs  than  naturally 
occurring compounds.
18 Therefore, others had opted to 
find new anti-inflammatory drug candidates from herbal 
plants or animals.
19,20 
A  large  number  of  the  previous  publications  primarily 
describe  the  involvement  of  variants  of  hepatic 
cytochrome  P450  that  metabolize  diclofenac  and 
sulindac (two other NSAIDs) and their toxic metabolites 
as  prime  suspects  in  generating  oxidative  stress.
10,15 
Interestingly however, the majority of such observations 
were  derived  either  from  intact  livers,  or  isolated 
hepatocyte models. Similar mechanism may be involved 
for mefenamic acid in the kidneys.  
Although mefenamic acid is an older NSAIDs, but it is 
still  being  prescribed  for  various  causes  in  developing 
countries  for  pain  syndrome  and  gynecological 
disorders.
1  Indeed,  the  studies  into  the  mechanism  of 
nephrotoxicity  are  vital  for  the  progress  of  this  drug. 
These  data  suggest  that  mefenamic  acid  causes 
nephrotoxicity  and  thus  warrants  circumspection  and 
appropriate  clinical  monitoring.  Indeed,  this  animal 
model  is  useful  for  the  study  of  the  mechanism  of 
nephrotoxicity induced by mefenamic acid. 
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